← All trials
NCT04563208
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 9, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Mar 31, 2021
- First posted
- Sep 24, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of the WitwatersrandLead sponsor
- University of the WitwatersrandReponsible party - principal investigator
- EzintshaOverall official - principal investigator
- SynaVirCollaborator
- SynaVirCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.